<html xmlns="http://www.w3.org/1999/xhtml" xmlns="http://www.w3.org/1999/xhtml">
 <head xmlns="http://www.w3.org/1999/xhtml">
 <title xmlns="http://www.w3.org/1999/xhtml"></title>
 </head>
 <body xmlns="http://www.w3.org/1999/xhtml">
 
 Innovus Pharmaceuticals, Inc. (&#34;Innovus Pharma&#34; or the "Company") (OTCQB 
 Venture Market: INNV), an emerging over-the-counter ("OTC") consumer 
 goods and specialty pharmaceutical company engaged in the 
 commercialization, licensing and development of safe and effective 
 non-prescription medicine and consumer care products to improve men's 
 and women's health and vitality and respiratory diseases, announced 
 today its plans to enter the oncology supportive care OTC market with an 
 exclusive license ("License") to two GRAS ("generally recognized as 
 safe" by the U.S. FDA)-listed compounds, thymol and carvacrol, for 
 cachexia and muscle growth and repair, from the University of Iowa 
 Research Foundation. Specifically, the License is to U.S. Patent 
 Application No. 15/509,438 "Use of Thymol and Carvacrol (monoterpene 
 phenols) for Induction of Increased Skeletal Muscle Endurance, lean 
 Muscle Mass and Reduced Adiposity," and all related foreign 
 worldwide patent applications.
 
 
 The compounds have shown in preclinical studies to induce an over 37% 
 increase in exercise tolerance and between a 15% to a 50% increase in 
 muscle mass of certain body muscles.
 
 
 "The oncology supportive care market is a very large unmet medical 
 market with limited choices to both physicians and patients," said Dr. 
 Bassam Damaj, the Chief Executive Officer of Innovus Pharma. "Companies 
 such as Abbott have been selling several hundred million dollars of its 
 powder medical foods such as Juven® into this market for years and we 
 believe that products we develop utilizing thymol and carvacrol could 
 add additional needed benefits and be more competitive in this field. 
 The treatment of cachexia just doesn't exist. It is a miserable frequent 
 event, that every physician knows about and many patients experience, 
 but there is simply little available against it and nothing to prevent 
 it," continued Dr. Damaj.
 
 
 Thymol and carvacrol are listed as GRAS substances by the FDA, meaning 
 that they are approved to be safely used in foods, drinks, nutritional 
 and dietary supplements.
 
 
 About Cachexia and Oncology Supportive Care Market
 
 
 The prominent feature in cachexia is weight loss and muscle wasting that 
 leads to progressive functional impairment; the loss of chest, diaphragm 
 and abdominal muscles that eventually erodes cardiopulmonary function is 
 often the ultimate cause of death for sufferers. It is a multifactorial 
 syndrome with many mechanisms involved, and is associated with several 
 chronic diseases including COPD, kidney disease, heart failure and in 
 particular cancer.
 
 
 The rate of cachexia in all cancer patients is anywhere around 40-50%, 
 and in pancreatic cancer it's about 80%. The National Cancer Institute 
 quoted 20-40% of cancer death is directly caused by cachexia.
 
 
 Current treatments for cachexia are essentially palliative care - 
 nutritional support, medications like steroids to build muscle and 
 exercise to maintain muscle function. According to Market Intel Reports 
 published on January 31, 2016, the U.S. market for cachexia is estimated 
 to be over $1 billion.
 
 
 About Muscle Growth and Repair Market
 
 
 In addition to the large cachexia market, the Company believes that the 
 two licensed compounds may eventually provide Innovus Pharma with 
 patented effective and safe new products in the general everyday muscle 
 repair and growth market. According to Forbes, the VMS (Vitamins, 
 Minerals and Supplements) market is estimated to be $60 billion by 2021.
 
 
 Juven® is a trademark owned by Abbott Laboratories ABT
 
 
 About Innovus Pharmaceuticals, Inc.
 
 
 Headquartered in San Diego, Innovus Pharma is an emerging 
 over-the-counter ("OTC") consumer goods and specialty pharmaceutical 
 company engaged in the commercialization, licensing and development of 
 safe and effective non-prescription medicine and consumer care products 
 to improve men's and women's health and vitality and respiratory 
 diseases. Innovus Pharma delivers innovative and uniquely presented and 
 packaged health solutions through its (a) OTC medicines and consumer and 
 health products, which we market directly, (b) commercial partners to 
 primary care physicians, urologists, gynecologists and therapists, and 
 (c) directly to consumers through our on-line channels, retailers and 
 wholesalers. The Company is dedicated to being a leader in developing 
 and marketing new OTC and branded Abbreviated New Drug Application 
 ("ANDA") products. The Company is actively pursuing opportunities where 
 existing prescription drugs have recently, or are expected to, change 
 from prescription (or Rx) to OTC.
 
 
 For more information, go to <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.innovuspharma.com&amp;esheet=51569414&amp;newsitemid=20170606005087&amp;lan=en-US&amp;anchor=www.innovuspharma.com&amp;index=1&amp;md5=f7b1c1f5b388da5137b74284377f8b7e" rel="nofollow" rel="nofollow">www.innovuspharma.com</a>, 
 <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.zestra.com&amp;esheet=51569414&amp;newsitemid=20170606005087&amp;lan=en-US&amp;anchor=www.zestra.com&amp;index=2&amp;md5=1a56663c92a06ba863f5f8e2ad6bf2c9" rel="nofollow" rel="nofollow">www.zestra.com</a>; 
 <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ejectdelay.com&amp;esheet=51569414&amp;newsitemid=20170606005087&amp;lan=en-US&amp;anchor=www.ejectdelay.com&amp;index=3&amp;md5=76e7997e843607c59572a319822b3dc2" rel="nofollow" rel="nofollow">www.ejectdelay.com</a>; 
 <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.myvesele.com&amp;esheet=51569414&amp;newsitemid=20170606005087&amp;lan=en-US&amp;anchor=www.myvesele.com&amp;index=4&amp;md5=1bb2bbd05c3cfbfc959483d32d46900c" rel="nofollow" rel="nofollow">www.myvesele.com</a>; 
 <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sensumplus.com&amp;esheet=51569414&amp;newsitemid=20170606005087&amp;lan=en-US&amp;anchor=www.sensumplus.com&amp;index=5&amp;md5=4f0672d010dc3ec67524837419c74541" rel="nofollow" rel="nofollow">www.sensumplus.com</a>; 
 <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.myandroferti.com&amp;esheet=51569414&amp;newsitemid=20170606005087&amp;lan=en-US&amp;anchor=www.myandroferti.com&amp;index=6&amp;md5=dbc506dc89bf611c7ee5942e32eca58d" rel="nofollow" rel="nofollow">www.myandroferti.com</a>; 
 <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fluticare.com&amp;esheet=51569414&amp;newsitemid=20170606005087&amp;lan=en-US&amp;anchor=www.fluticare.com&amp;index=7&amp;md5=7f9e263b55ae385d83327d8e79f7f874" rel="nofollow" rel="nofollow">www.fluticare.com</a>; 
 <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.beyondhumantestosterone.com&amp;esheet=51569414&amp;newsitemid=20170606005087&amp;lan=en-US&amp;anchor=www.beyondhumantestosterone.com&amp;index=8&amp;md5=4073e73ab3f94d16244172aa3461e22f" rel="nofollow" rel="nofollow">www.beyondhumantestosterone.com</a>; 
 <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.getbeyondhuman.com&amp;esheet=51569414&amp;newsitemid=20170606005087&amp;lan=en-US&amp;anchor=www.getbeyondhuman.com&amp;index=9&amp;md5=e205cd3e9dae278cc0ac81123a02434e" rel="nofollow" rel="nofollow">www.getbeyondhuman.com</a>; 
 <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.trybeyondhuman.com&amp;esheet=51569414&amp;newsitemid=20170606005087&amp;lan=en-US&amp;anchor=www.trybeyondhuman.com&amp;index=10&amp;md5=73b3875bd62dd20920ddcbf64662bbf2" rel="nofollow" rel="nofollow">www.trybeyondhuman.com</a>; 
 <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.prostagorx.com&amp;esheet=51569414&amp;newsitemid=20170606005087&amp;lan=en-US&amp;anchor=www.prostagorx.com&amp;index=11&amp;md5=b4b7f7256c7df41a4fdbfeaa4f7faadf" rel="nofollow" rel="nofollow">www.prostagorx.com</a>; 
 <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.allervarx.com&amp;esheet=51569414&amp;newsitemid=20170606005087&amp;lan=en-US&amp;anchor=www.allervarx.com&amp;index=12&amp;md5=9c95feb5afbab5519fb4f7da3aa5c9bc" rel="nofollow" rel="nofollow">www.allervarx.com</a>; 
 and <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fluticare.com&amp;esheet=51569414&amp;newsitemid=20170606005087&amp;lan=en-US&amp;anchor=www.fluticare.com&amp;index=13&amp;md5=fbb59a8a773ff8c84f77a933cff15897" rel="nofollow" rel="nofollow">www.fluticare.com</a>
 
 
 Innovus Pharma&#39;s Forward-Looking Safe Harbor
 
 
 Statements under the Private Securities Litigation Reform Act, as 
 amended: with the exception of the historical information contained in 
 this release, the matters described herein contain forward-looking 
 statements that involve risks and uncertainties that may individually or 
 mutually impact the matters herein described for a variety of reasons 
 that are outside the control of the Company, including, but not limited 
 to, receiving patent protection in the U.S. and abroad relating to its 
 licensed patent applications from the University of Iowa Foundation and 
 for other technologies and products, to successfully commercialize such 
 and other products in the U.S. and throughout the world and to achieve 
 its other development, commercialization, financial and staffing 
 objectives. Readers are cautioned not to place undue reliance on these 
 forward-looking statements as actual results could differ materially 
 from the forward-looking statements contained herein. Readers are urged 
 to read the risk factors set forth in the Company&#39;s most recent filing 
 on Form S-1, annual report on Form 10-K, subsequent quarterly reports 
 filed on Form 10-Q and other filings made with the SEC. Copies of these 
 reports are available from the SEC&#39;s website or without charge from the 
 Company.
 
 
 
 <img xmlns="http://www.w3.org/1999/xhtml" alt="" src="http://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20170606005087r1&amp;sid=benz2&amp;distro=nx&amp;lang=en"></img>View source version on businesswire.com: <a xmlns="http://www.w3.org/1999/xhtml" href="http://www.businesswire.com/news/home/20170606005087/en/" rel="nofollow" rel="nofollow">http://www.businesswire.com/news/home/20170606005087/en/</a></body></html>

Press Releases

Innovus Pharma to Enter the Oncology Supportive Care Market With an Exclusive License to Two GRAS-Listed OTC Compounds for Cachexia and Muscle Growth and Repair From the University of Iowa Research Foundation - Abbott Laboratories (NYSE:ABT), InnovAge Holding (NASDAQ:INNV)

Abbott Laboratories

InnovAge Holding

INNV

Innovus Pharma to Enter the Oncology Supportive Care Market With an Exclusive License to Two GRAS-Listed OTC Compounds for Cachexia and Muscle Growth and Repair From the University of Iowa Research Foundation

ASLE


AerSale Corporation (NASDAQ:ASLE) (&#34;AerSale&#34;) announced a favorable recommendation by a U.S. Federal Magistrate Judge in AerSale&#39;s lawsuit with Jetaire Aerospace, LLC, Jetaire Flight Systems, LLC (collectively

U.S. Federal Magistrate Judge Recommends Invalidation of Jetaire Patents in Lawsuit Against AerSale

RiverNorth Marketplace Lending Corporation Common Stock


RiverNorth Opportunities Fund, Inc., RiverNorth/DoubleLine Strategic Opportunity Fund, Inc. and RiverNorth Capital and Income Fund, Inc. are each pleased to announce the declaration of preferred dividends for the second

RiverNorth Opportunities Fund, Inc., RiverNorth/DoubleLine Strategic Opportunity Fund, Inc. and RiverNorth Capital and Income Fund, Inc. Announce Preferred Dividends


Biloxi Marsh Lands Corporation has posted its unaudited results for the first quarter of 2024 on the Company&#39;s website www.biloximarshlandscorp.com.


The Company has received written notice of termination of the CO2

Biloxi Marsh Lands Corporation Announces Unaudited Results for the First Quarter of 2024

EWBC


East West Bancorp, Inc. (&#34;East West&#34; or the &#34;Company&#34;) (NASDAQ:EWBC), announced today that Christopher Del Moral-Niles, Chief Financial Officer, will meet with investors and discuss East West&#39;s business, performance,

East West Bancorp to Attend the Wells Fargo 2024 Financial Services Investor Conference


The law firm of Federman &amp; Sherwood has initiated an investigation into Kisco Senior Living, LLC with respect to their recent data breach. On June 6, 2023, Kisco experienced a network disruption and immediately took

Federman &amp; Sherwood Investigates Kisco Senior Living, LLC for Data Breach

VTMX


Corporación Inmobiliaria Vesta, S.A.B. de C.V. (&#34;Vesta&#34; the &#34;Company&#34;) (NYSE:VTMX), hereby announces that on April 19, 2024, Vesta filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 (the